Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

72 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Venous thrombosis in children and adolescents with Hodgkin lymphoma in Sweden.
Schönning A, Karlén J, Frisk T, Heyman M, Svahn JE, Øra I, Kawan L, Holmqvist BM, Björklund C, Harila-Saari A, Ranta S. Schönning A, et al. Among authors: karlen j. Thromb Res. 2017 Apr;152:64-68. doi: 10.1016/j.thromres.2017.02.011. Epub 2017 Feb 16. Thromb Res. 2017. PMID: 28249199
18F-FDG PET Response of Skeletal (Bone Marrow and Bone) Involvement After Induction Chemotherapy in Pediatric Hodgkin Lymphoma: Are Specific Response Criteria Required?
Georgi TW, Kluge R, Kurch L, Chavdarova L, Hasenclever D, Stoevesandt D, Pelz T, Landman-Parker J, Wallace WH, Karlen J, Fernández-Teijeiro A, Cepelova M, Fosså A, Balwierz W, Attarbaschi A, Ammann RA, Pears J, Hraskova A, Uyttebroeck A, Beishuizen A, Dieckmann K, Leblanc T, Daw S, Baumann J, Körholz D, Sabri O, Mauz-Körholz C. Georgi TW, et al. Among authors: karlen j. J Nucl Med. 2018 Oct;59(10):1524-1530. doi: 10.2967/jnumed.117.205633. Epub 2018 Apr 13. J Nucl Med. 2018. PMID: 29653979 Free article.
Comparison of Interim PET Response to Second-Line Versus First-Line Treatment in Classic Hodgkin Lymphoma: Contribution to the Development of Response Criteria for Relapsed or Progressive Disease.
Kluge R, Wittig T, Georgi TW, Kurch L, Sabri O, Wallace WH, Klekawka T, Fernández-Teijeiro A, Ceppi F, Karlén J, Pears J, Cepelová M, Fosså A, Beishuizen A, Hjalgrim LL, Körholz D, Mauz-Körholz C, Hasenclever D. Kluge R, et al. Among authors: karlen j. J Nucl Med. 2021 Mar;62(3):338-341. doi: 10.2967/jnumed.120.247924. Epub 2020 Aug 6. J Nucl Med. 2021. PMID: 32764122 Free article.
Assessment of Waldeyer's ring in pediatric and adolescent Hodgkin lymphoma patients-Importance of multimodality imaging: Results from the EuroNet-PHL-C1 trial.
Kurch L, Mauz-Körholz C, Fosså A, Georgi TW, Kluge R, Bartelt JM, Kunze C, Wohlgemuth WA, Pelz T, Vordermark D, Plößl S, Hasenclever D, Sabri O, Landman-Parker J, Wallace WH, Karlen J, Fernández-Teijeiro A, Cepelova M, Klekawka T, Løndalen AM, Steiner D, Krombach G, Attarbaschi A, Hoffmann M, Ceppi F, Pears J, Hraskova A, Uyttebroeck A, Beishuizen A, Dieckmann K, Leblanc T, Daw S, Körholz D, Stoevesandt D. Kurch L, et al. Among authors: karlen j. Pediatr Blood Cancer. 2021 Apr;68(4):e28903. doi: 10.1002/pbc.28903. Epub 2021 Feb 3. Pediatr Blood Cancer. 2021. PMID: 33538093 Free article. Clinical Trial.
Response-adapted omission of radiotherapy and comparison of consolidation chemotherapy in children and adolescents with intermediate-stage and advanced-stage classical Hodgkin lymphoma (EuroNet-PHL-C1): a titration study with an open-label, embedded, multinational, non-inferiority, randomised controlled trial.
Mauz-Körholz C, Landman-Parker J, Balwierz W, Ammann RA, Anderson RA, Attarbaschi A, Bartelt JM, Beishuizen A, Boudjemaa S, Cepelova M, Claviez A, Daw S, Dieckmann K, Fernández-Teijeiro A, Fosså A, Gattenlöhner S, Georgi T, Hjalgrim LL, Hraskova A, Karlén J, Kluge R, Kurch L, Leblanc T, Mann G, Montravers F, Pears J, Pelz T, Rajić V, Ramsay AD, Stoevesandt D, Uyttebroeck A, Vordermark D, Körholz D, Hasenclever D, Wallace WH. Mauz-Körholz C, et al. Among authors: karlen j. Lancet Oncol. 2022 Jan;23(1):125-137. doi: 10.1016/S1470-2045(21)00470-8. Epub 2021 Dec 9. Lancet Oncol. 2022. PMID: 34895479 Free PMC article. Clinical Trial.
Hodgkin lymphoma: hypodense lesions in mediastinal masses.
Damek A, Kurch L, Franke FC, Attarbaschi A, Beishuizen A, Cepelova M, Ceppi F, Daw S, Dieckmann K, Fernández-Teijeiro A, Feuchtinger T, Flerlage JE, Fosså A, Georgi TW, Hasenclever D, Hraskova A, Karlen J, Klekawka T, Kluge R, Körholz D, Landman-Parker J, Leblanc T, Mauz-Körholz C, Metzler M, Pears J, Steglich J, Uyttebroeck A, Vordermark D, Wallace WH, Wohlgemuth WA, Stoevesandt D. Damek A, et al. Among authors: karlen j. Sci Rep. 2024 Jun 25;14(1):14591. doi: 10.1038/s41598-024-64253-8. Sci Rep. 2024. PMID: 38918503 Free PMC article.
Inter-Reader Reliability of Early FDG-PET/CT Response Assessment Using the Deauville Scale after 2 Cycles of Intensive Chemotherapy (OEPA) in Hodgkin's Lymphoma.
Kluge R, Chavdarova L, Hoffmann M, Kobe C, Malkowski B, Montravers F, Kurch L, Georgi T, Dietlein M, Wallace WH, Karlen J, Fernández-Teijeiro A, Cepelova M, Wilson L, Bergstraesser E, Sabri O, Mauz-Körholz C, Körholz D, Hasenclever D. Kluge R, et al. Among authors: karlen j. PLoS One. 2016 Mar 10;11(3):e0149072. doi: 10.1371/journal.pone.0149072. eCollection 2016. PLoS One. 2016. PMID: 26963909 Free PMC article. Clinical Trial.
Response-adapted omission of radiotherapy in children and adolescents with early-stage classical Hodgkin lymphoma and an adequate response to vincristine, etoposide, prednisone, and doxorubicin (EuroNet-PHL-C1): a titration study.
Mauz-Körholz C, Landman-Parker J, Fernández-Teijeiro A, Attarbaschi A, Balwierz W, Bartelt JM, Beishuizen A, Boudjemaa S, Cepelova M, Ceppi F, Claviez A, Daw S, Dieckmann K, Fosså A, Gattenlöhner S, Georgi T, Hjalgrim LL, Hraskova A, Karlén J, Kurch L, Leblanc T, Mann G, Montravers F, Pears J, Pelz T, Rajić V, Ramsay AD, Stoevesandt D, Uyttebroeck A, Vordermark D, Körholz D, Hasenclever D, Wallace WH, Kluge R. Mauz-Körholz C, et al. Among authors: karlen j. Lancet Oncol. 2023 Mar;24(3):252-261. doi: 10.1016/S1470-2045(23)00019-0. Lancet Oncol. 2023. PMID: 36858722 Free article. Clinical Trial.
72 results